Page 35 - Pharma Sector

Global abortion pill provider buys from Indian firm with bad quality record

More than 30 samples of drugs made by Delhi-based Synokem Pharmaceuticals Ltd have failed quality tests conducted by Indian regulators

CVS Health Corp to cut 5,000 jobs amid shift away from retail focus

None of the job losses will impact customer-facing positions in stores, pharmacies, clinics or customer services centers, a spokesman for the company said

Glenmark Pharmaceuticals gets USFDA nod to market generic diabetes drug

Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in the American market. The company has received final approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets (2.5 mg and 5 mg), the generic version of AstraZeneca's Onglyza1 tablets, the Mumbai-based drug maker said in a statement. According to IQVIATM sales data, for the 12-month period ending June 2023, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 100.7 million. Glenmark said its current portfolio now consists of 184 products authorized for distribution in the US market and 49 abbreviated new drug applications (ANDAs) are pending approval with the US FDA.

Top headline: Govt hikes windfall tax on petroleum crude, Nuh violence

Business Standard brings you the top headlines at this hour

In-home cardio care: Lupin Digital, American College of Cardiology tie up

The aim is to give patients and healthcare providers tools to manage heart diseases at home and reduce rehospitalisation

China eyes next pandemic in push for new medical emergency facilities

The facilities will be used for tourism, recreation and healthcare in normal times. During emergencies, they will serve as medical treatment and quarantine centers

WHO seeks help from India in latest toxic syrup-deaths case in Cameroon

The alert about Naturcold is the latest of several similar warnings issued in recent months about contaminated cough syrups sold worldwide

Lupin gets thumbs up from USFDA to market generic medication in US

Drug firm Lupin on Friday said its unit has received approval from the US health regulator to market a medication to treat various disorders like schizophrenia. The company's Somerset-based wholly-owned subsidiary Lupin Inc has received approval from the US Food and Drug Administration (USFDA) for Chlorpromazine Hydrochloride tablets, Lupin said in a statement. The Mumbai-based drug maker's product is the generic version of Upsher-Smith Laboratories, LLC's product. As per IQVIA MAT data, Chlorpromazine Hydrochloride Tablets had an estimated annual sale of USD 45 million in the US.

Nirma, Sekhmet Pharmaventures vie for $731 mn Glenmark Life stake: Reports

Suitors have entered final round of bidding for stake of about 83% in Mumbai-listed company held by Glenmark Pharmaceuticals Ltd., said people, who asked not to be identified as information is private

Q1 preview: US drug shortage, stable pricing set to boost pharma revenues

Hospitals are, however, likely to report lower occupancy rates, and diagnostics companies may witness an impact from delayed monsoon

Have taken regulatory action against 105 pharma companies: Health minister

Mandaviya said that after 137 firms were inspected, production has been stopped at 31 companies and the product licenses of 50 firms have been cancelled

Top Headlines: Lapses in pharma regulation, IPL's valuation rises 80%

Business Standard brings you the top headlines at this hour

Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

Manipal Group likely to inject Rs 1,000 cr into PharmEasy for 18% stake

Omnichannel pharmacy chain in talks to raise ~2,400 cr: if successful, will be first fundraise by a unicorn at a discount

Biocon Biologics biosimilar available in US, to treat inflammatory diseases

Biocon Biologics, a subsidiary of Biocon, on Monday said its biosimilar to treat certain inflammatory diseases is now available in the US market. The company said HULIO (adalimumab) injection, a biosimilar to Humira (adalimumab), is now available to patients in the US after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosimilar adalimumab, in the US, is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the US," Biocon Biologics CEO and MD Shreehas Tambe said in a statement. This launch builds on the company's strong presence in oncology and diabetes, he added.

Lupin receives US regulator's approval for Cyanocobalamin nasal spray

The nasal spray manufactured by Lupin is a generic version of Nascobal nasal spray

Lupin gets $25 mn from AbbVie for meeting key product development milestone

Drug firm Lupin on Thursday said it has received USD 25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers, the Mumbai-based drug maker said in a statement. As part of the agreement, Lupin has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully, it added. The drug maker had earlier received USD 30 million from AbbVie for achievement of other milestones in the programme. "This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continued successful development of this important treatment for patients with difficult-to-treat cancers," Lupin Managing Directo

Akums gets nod for drug to treat epilepsy seizures in patients over 12 yrs

Contract manufacturing drug firm Akums Drugs & Pharmaceuticals on Tuesday said DCGI has approved its formulation to treat certain types of seizures in patients with epilepsy. The approval allows Perampanel Oral Suspension to serve as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalised seizures, as well as primary generalised tonic-clonic (PGTC) seizures in patients with epilepsy aged 12 years and older in the country, the company said in a statement. The company's product is a bioequivalent formulation of the USFDA-approved Fycompa (perampanel) Oral Suspension. India has more than 10 million patients with epilepsy, as per the company. "We are excited about the approval of Perampanel Oral Suspension, as it provides another treatment option for patients with epilepsy who may have difficulty swallowing tablets or prefer liquids," Akums Drugs & Pharmaceuticals Joint Managing Director Sanjeev Jain stated. The newly-approved ..

First medicine designed by AI soon? Insilico Medicine begins human trials

The biotech firm has dosed a patient in China with its drug INS018_055 to treat the chronic lung disease idiopathic pulmonary fibrosis

Govt launches Nandi portal for granting NOC for veterinary drugs, vaccines

Union Minister Parshottam Rupala on Monday launched a Nandi portal to timely process applications and grant non-objection certification (NOC) for veterinary drugs and vaccines. The regulation of the import, manufacturing and marketing of veterinary drugs and vaccines comes under the purview of the Central Drug Standard Control Organization (CDSCO) under the Ministry of Health. However, permission for the import/manufacture of veterinary drugs, vaccines and biological are granted in consultation with the Ministry of Fisheries, Animal Husbandry and Dairying. The present system is manual. "The Health Ministry gives final approval of drugs and vaccines. In the case of veterinary products, it cannot give without the NOC from us. Since granting of NOC was manual, delay/obstacle from our ministry was felt. So, the portal NANDI (NOC Approval for New Drug and Inoculation System) has been launched," the Fisheries, Animal Husbandry and Dairying Minister said after the launch. This is a timely